Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Dosing Protocols: Clinical Comparison

Standard HIV Lipodystrophy 2mg SC daily 26 weeks 15.2 18 +42 Gold standard. Maximal efficacy with acceptable tolerability Low-Dose Continuous 1mg SC daily 52 weeks 9.8 11 +28 Lower efficacy but improved long-term adherence in sensitive individuals High-Dose Sh

This comparison does not assign a generated winner or score.

  • Standard HIV Lipodystrophy
  • 2mg SC daily
  • 26 weeks
  • 15.2
  • 18
  • +42
  • Gold standard. Maximal efficacy with acceptable tolerability
  • Low-Dose Continuous
  • 1mg SC daily
  • 52 weeks
  • 9.8
  • 11
  • +28
  • Lower efficacy but improved long-term adherence in sensitive individuals
  • High-Dose Short-Term
  • 3mg SC daily
  • 12 weeks
  • 11.4
  • 29
  • +61
  • Higher side effects without proportional benefit. Not recommended
  • Intermittent Dosing (5 days on, 2 off)
  • 2mg SC on dosing days
  • 12.7
  • 14
  • +38
  • Slightly reduced efficacy but may improve receptor sensitivity over time